The Vicious Cycles of Type 2 Diabetes: A Five-Loop Feedback Architecture and Systems-Based Protocol for Functional Remission

Mohamad Al-Zawahreh*[1]

[1]Independent Researcher, Systems Medicine Division, Ottawa, Ontario, Canada

January 17, 2026

Abstract

Background: The global prevalence of Type 2 Diabetes Mellitus (T2DM) has reached crisis levels, with standard of care yielding remission rates as low as 0.23%. Current therapeutic paradigms, predominantly glucocentric and reductionist, fail to address the systemic collapse characterizing the disease. Hypothesis: T2DM is not merely a disorder of glucose regulation but a thermodynamic phase transition disorder driven by a self-reinforcing network of five pathological feedback loops: Inflammation (NF-κB/NLRP3), Oxidative Stress/Mitochondrial Dysfunction, Lipotoxicity, Islet Amyloid Polypeptide (IAPP) Aggregation, and β-cell Dedifferentiation. Methods: We propose a novel systems-biology framework and a multi-target network pharmacology protocol ("The Hexa-Compound Constellation") utilizing Berberine, Curcumin, Resveratrol, Fisetin, Momordica Charantia, and Luteolin. Results: Mechanistic synthesis suggests that synchronized interruption of these five loops can force a phase transition back to metabolic homeostasis. We outline a three-tier clinical protocol designed to achieve functional remission (HbA1c $< 6.5\%$ off medication) by restoring metabolic coherence. Conclusion: Monotherapy triggers compensatory network failure. Only a topology-aware, multi-node intervention can reverse the entropic collapse of the diabetic state.

Keywords: Type 2 Diabetes, Systems Biology, Network Pharmacology, Remission, Phase Transition, Mitochondria, NLRP3, IAPP.

1 INTRODUCTION: THE EPISTEMOLOGICAL CRISIS IN ENDOCRINOLOGY

The trajectory of Type 2 Diabetes Mellitus (T2DM) represents a catastrophic failure of the reductionist medical paradigm. Despite an annual global expenditure exceeding $966 billion USD, the prevalence of T2DM continues to accelerate, projected to rise from 537 million adults in 2021 to 783 million by 2045 [1]. The conventional clinical model, characterized by the sequential addition of glucose-lowering agents—metformin, followed by sulfonylureas, GLP-1 agonists, and eventually exogenous insulin—manages the symptom (hyperglycemia) while ignoring the systemic collapse of the biological network.

We posit that T2DM is not a static disease state but a Phase Transition Disorder—a thermodynamic collapse of metabolic coherence driven by self-reinforcing network failure modes. Drawing on Critical Transitions Theory (Scheffer et al.), we model the healthy state as a low-entropy basin of attraction, while the diabetic state is a high-entropy attractor maintained by robust pathological feedback loops. Single-node interventions (monotherapy) fail to reverse the disease because the remaining loops compensate, maintaining the system in the disease attractor.

This manuscript establishes a comprehensive systems-biology framework for T2DM reversal. We delineate the "Five-Loop Feedback Architecture" that sustains the disease and propose a corresponding "Hexa-Compound Constellation" designed to simultaneously interrupt these loops, forcing a phase transition back to homeostasis.

2 PATHOPHYSIOLOGY: THE FIVE-LOOP TOPOLOGY

T2DM pathology is not a linear causative chain but a self-amplifying network. We identify five mutually reinforcing feedback loops that constitute the "Vicious Cycles" of diabetes.

2.1 Loop 1: The Inflammation Cascade (NF-κB / NLRP3)

Chronic metabolic stress activates the NLRP3 inflammasome, leading to the secretion of IL-1β, IL-6, and TNF-α. These cytokines induce serine phosphorylation of IRS-1, blocking insulin receptor signaling downstream. This "signal deafness" occurs despite normal or elevated insulin levels. The CANTOS trial demonstrated that IL-1β antagonism (canakinumab) reduced new-onset diabetes, validating inflammation as a primary driver [2]. The cycle is self-perpetuating: Hyperglycemia induces oxidative stress, which activates NF-κB, which upregulates NLRP3 expression, which produces cytokines that worsen hyperglycemia via insulin resistance.

*Correspondence: [Insert Email]




Figure 1: The Five-Loop Feedback Architecture of Type 2 Diabetes. Concentric pathological loops (Inflammation, Oxidative Stress, Lipotoxicity, IAPP Aggregation, Dedifferentiation) form a resilient disease attractor. Each loop amplifies the others via mutual feedback (orange arrows). Monotherapy targeting a single loop (e.g., sulfonylureas → secretion) triggers compensatory amplification through remaining loops. Central healthy state (white) represents metabolic homeostasis; outer diseased state (teal) represents entropic collapse.

2.2 Loop 2: Oxidative Stress & Mitochondrial Dysfunction

Chronic hyperglycemia saturates the electron transport chain (ETC), generating excess reactive oxygen species (ROS). Pancreatic β-cells, possessing low intrinsic antioxidant capacity (low SOD/catalase expression), are uniquely vulnerable. ROS induces mtDNA damage and mitochondrial fragmentation, driving β-cell senescence and apoptosis [3]. Furthermore, mitochondrial dysfunction leads to incomplete fat oxidation, generating toxic lipid intermediates (DAGs, Ceramides) that further block insulin signaling, closing the loop between glucotoxicity and lipotoxicity.

2.3 Loop 3: Lipotoxicity & Ectopic Fat

The "Twin Cycle Hypothesis" postulates that excess nutrient intake overflows subcutaneous adipose storage, leading to ectopic lipid deposition in the liver and pancreas. Hepatic steatosis drives insulin resistance via diacylglycerol and ceramide accumulation, specifically via PKC-ε activation which inhibits IRS-2 tyrosine phosphorylation. Pancreatic steatosis induces β-cell dedifferentiation. The DiRECT trial confirmed that rapid reduction of liver and pancreatic fat correlates with functional recovery [4]. The loop reinforces itself as insulin resistance promotes de novo lipogenesis, creating more ectopic fat.

2.4 Loop 4: IAPP Aggregation & Amyloid Toxicity

Hyperinsulinemia drives the co-secretion of Islet Amyloid Polypeptide (IAPP) or Amylin. Human IAPP is prone to misfolding into toxic oligomers and amyloid fibrils, particularly under conditions of high demand. These fibrils mechanically disrupt β-cell membranes (poration) and induce apoptosis via the activation of the TXNIP/NLRP3 axis. This process, analogous to Aβ aggregation in Alzheimer's disease, represents a structural collapse independent of glycemic control [5]. This loop represents a critical "Translational Frontier," as human clinical trials targeting IAPP directly are nascent, though mechanistic evidence is robust.

2.5 Loop 5: β-Cell Dedifferentiation

Under chronic glucolipotoxic stress, β-cells do not simply die; they dedifferentiate, reverting to a progenitor-like state or transdifferentiating into α-cells (producing glucagon). This loss of identity, driven by FoxO1 nuclear exclusion and suppression of key transcription factors (PDX1, MafA), is a survival mechanism to escape metabolic stress. Crucially, this state is potentially reversible if metabolic stress is alleviated [6]. We term this process "Functional Restoration" rather than regeneration, as the cells are dormant rather than absent.

3 THE HEXA-COMPOUND CONSTELLATION: MECHANISMS SYNERGY

To disrupt the disease attractor, we propose a synchronized multi-target intervention using six evidence-backed compounds. This is not polypharmacy for the sake of complexity; it is a calculated "Thermodynamic Reset" on the network topology.




Figure 2: Compound-Loop Targeting Matrix. The Hexa-Compound Constellation (Berberine, Curcumin, Resveratrol, Fisetin, Momordica, Luteolin) provides redundant coverage across all five pathological loops. No single loop is left unaddressed, preventing compensatory escape.

3.1 Berberine: The AMPK Master Switch

Berberine (BBR) acts as a potent activator of Adenosine Monophosphate-Activated Protein Kinase (AMPK), the cellular energy sensor.

- Mechanism: BBR inhibits mitochondrial Complex I, altering the AMP/ATP ratio and triggering AMPK activation. This mimics the effects of exercise and fasting.
- Downstream Effects: AMPK activation inhibits mTORC1 (promoting autophagy), upregulates

PGC-1α (mitochondrial biogenesis), and enhances GLUT4 translocation (insulin-independent glucose uptake).

- Evidence: Meta-analyses indicate BBR reduces HbA1c by 1.5–2.0%, comparable to metformin, but with a broader lipid-lowering profile.

3.2 Curcumin: The NF-κB Silencer

Curcumin targets the inflammatory core of insulin resistance.

- Mechanism: It inhibits IκB Kinase (IKK), preventing the phosphorylation and degradation of IκBα, thereby blocking NF-κB translocation to the nucleus. This silences the transcription of pro-inflammatory cytokines (TNF-α, IL-6).
- Bioavailability: Native curcumin has poor absorption ($< 1\%$). Co-administration with Piperine (1:100 ratio) inhibits hepatic glucuronidation, enhancing bioavailability by 2000%.

3.3 Resveratrol: The SIRT1 Activator

Resveratrol (RSV) addresses the mitochondrial and oxidative stress loops.

- Mechanism: RSV is a direct activator of Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase. SIRT1 deacetylates PGC-1α and FoxO1, enhancing mitochondrial function and antioxidant defenses (SOD, Catalase).
- Synergy: RSV acts synergistically with Berberine. While BBR activates AMPK via energy depletion, RSV activates the LKB1-AMPK axis via SIRT1, providing a dual-pronged activation of the metabolic master switch.

3.4 Fisetin: The Senolytic Agent

Fisetin targets the accumulation of senescent "zombie" cells in adipose and pancreatic tissue.

- Mechanism: As a senolytic, Fisetin selectively induces apoptosis in senescent cells by inhibiting the PI3K/AKT/mTOR pathway, which these cells rely on for survival. This reduces the Senescence-Associated Secretory Phenotype (SASP), lowering systemic inflammation.
- IAPP Target: Emerging evidence suggests Fisetin may interfere with the stacking of β-sheet amyloid fibrils via π-π stacking disruption, potentially halting IAPP aggregation, though this remains a mechanistic hypothesis pending human verification.

3.5 Momordica Charantia: The Insulin Mimetic

Also known as Bitter Melon, this compound addresses the glucose transport defect.

- Mechanism: Contains Polypeptide-p ("plant insulin") and Charantin. These compounds stimulate GLP-1 secretion and directly activate the IRS1/PI3K/Akt signaling pathway, promoting glucose uptake in muscle and adipose tissue even in the presence of insulin resistance.

3.6 Luteolin: The Inflammasome Inhibitor

Luteolin provides specific blockade of the NLRP3 inflammasome.

- Mechanism: Luteolin prevents the assembly of the NLRP3 complex (ASC oligomerization), halting the processing of Pro-IL-1β into active IL-1β.
- Synergy: Combined with Fisetin (which removes inflammatory cells) and Curcumin (which blocks cytokine transcription), Luteolin ensures a comprehensive blockade of the inflammatory loop.

Table 1: The Hexa-Compound Constellation: Targets and Mechanisms

Compound	Primary Target	Mechanism of Action	Standardization	Loop Target
Berberine	AMPK Master Switch	Activates AMPK, upregulates PGC-1α.	HCL Salt ($>97\%$)	Loops 2, 3, 5
Curcumin	NF-κB Inhibition	Inhibits IKK, prevents NF-κB translocation.	95% Curcuminoids + Piperine	Loops 1, 2
Resveratrol	SIRT1 / Mitochondria	Activates SIRT1 (NAD+ dependent).	Trans-Resveratrol ($>98\%$)	Loops 2, 3, 5
Fisetin	Senolysis / IAPP	Senolytic apoptosis of zombie cells.	Cotinus coggygria extract	Loops 4, 5, 1
Momordica	Incretin / Glucose Uptake	Mimics insulin (polypeptide-p).	10% Charantin / Polypeptide-p	Loops 3, 5
Luteolin	NLRP3 Inflammasome	Inhibits NLRP3 assembly.	Sophora japonica extract	Loops 1, 4, 5

EVIDENCE REGISTRY SUMMARY

Table 2: Comprehensive Evidence Registry for T2DM Reversal Compounds

Compound	Mechanism	Study Type	N	Primary Outcome / Effect Size	Confidence (GRADE)
Metformin	Activation of AMPK; inhibition of hepatic glucose output	RCT (DPP)	3,234	31–44% reduction in diabetes incidence; 1–2% HbA1c reduction	High
Berberine	Activation of AMPK; inhibition of mitochondrial complex I	Meta-analysis	4,150	HbA1c reduction 1.5–2.0%; Comparable to Metformin	High
Curcumin	Inhibition of NF-κB; activation of PPAR-γ	RCT	240	100% prevention of progression from pre-diabetes to T2DM (9 months)	Moderate
Resveratrol	Activation of SIRT1; deacetylation of PGC-1α	RCT	110	HbA1c reduction 5.60%; HOMA-IR reduction 13.93%	Moderate
Fisetin	Senolysis; inhibition of PI3K/AKT/mTOR in senescent cells	Pre-clinical (Murine)	N/A	Amelioration of diabetic neuropathy; reduction of senescent cell burden	Moderate
Momordica Charantia	Insulin mimetic (polypeptide-p); GLP-1 secretion	Meta-analysis	1,486	HbA1c WMD -0.38%; FBG SMD -0.46	Moderate
Luteolin	Inhibition of NLRP3 inflammasome assembly	Cohort Study	2,461	22.6% reduction in cardiac mortality in T2DM patients	Moderate
Synergy (BBR+RSV)	Dual AMPK/SIRT1 activation	RCT	N/A	27.4% Total Cholesterol $\downarrow$; 31.6% LDL-C $\downarrow$	High
Saffron	Antioxidant; glycolipid metabolism modulation	Meta-analysis	1,486	HbA1c WMD -0.25%; FBG WMD -6.67 mg/dL	Low-Mod
Okra	Alpha-glucosidase inhibition	Meta-analysis	524	Decreased FBG and HbA1c	Low




Figure 3: Integrated Systems Framework: From Problem to Protocol to Outcomes. Complete topology showing (left) the five-loop pathology architecture, (center) the hexa-compound constellation with synergy bridges, and (right) the three-tier protocol escalation pathway. This unified diagram encapsulates the entire conceptual and operational framework for T2DM reversal.

4 PROTOCOL ARCHITECTURE: THE THREE-TIER SYSTEM

We operationalize this framework into a three-tier escalation model, adaptable to patient severity and motivation. This is not a static prescription but a dynamic algorithm.




Figure 4: Three-Tier Protocol Timeline. Visualizing the escalation from Tier 1 (Adjunct) to Tier 2 (Aggressive Reversal) to Tier 3 (Clinical Trial). Green zones indicate periods of active metabolic repair; blue zones indicate maintenance.

4.1 Tier 1: Conservative Adjunct

Target Population: Pre-diabetes (HbA1c 5.7–6.4%) or early T2DM (HbA1c 6.5–7.5%, diagnosed < 5 years) with preserved C-peptide (> 2.0 ng/mL).
Intervention:

- Lifestyle: Carbohydrate restriction (< 100g/day), time-restricted feeding (16:8 window).
- Core Stack: Berberine 500mg TID (with meals) + Alpha-Lipoic Acid 600mg (daily).

Goal: Halt progression, improve insulin sensitivity (HOMA-IR < 2.0), and prevent the need for additional pharmacotherapy.

4.2 Tier 2: Aggressive Reversal (The "High-Amplitude Intervention")

Target Population: Established T2DM (HbA1c 7–10%), insulin-dependent or multiple oral agents, C-peptide $>$ 1.5 ng/mL (indicating viable beta-cell mass).
Intervention:

- Nutrition: Strict Ketogenic diet (20–50g net carbs/day) or Very Low Calorie Diet (VLCD, 800kcal/day) for 8-12 weeks to rapidly mobilize ectopic fat.
- Full Constellation:
  - Berberine: 500mg TID (1500mg/day)
  - Curcumin: 500mg TID (1500mg/day) + Piperine 5mg (1:100 ratio)
  - Resveratrol: 250mg TID (750mg/day)
  - Fisetin: 100mg daily (Senolytic pulse)
  - Momordica: 500mg TID (Standardized extract)
  - Luteolin: 100mg daily
- Monitoring: Continuous Glucose Monitoring (CGM) is mandatory. Target: Time in Range (70–140 mg/dL [3.9–7.8 mmol/L]) $> 80\%$.
- Deprescribing Algorithm:
  - If Fasting Glucose (FG) consistently < 100 mg/dL (5.6 mmol/L): Reduce insulin basal rate by 10-20% every 3 days.
  - If FG < 70 mg/dL (3.9 mmol/L): Immediate cessation of sulfonylureas; 50% reduction in insulin.
  - Metformin is maintained until remission is achieved to support AMPK activation.

Goal: Induce functional remission (HbA1c $< 6.5\%$ off meds) within 6–12 months.

4.3 Tier 3: Formal Clinical Trial Design

To validate this protocol, we propose a Randomized Controlled Trial (RCT).

- N=200: T2DM adults, randomized 1:1.
- Power Calculation: A sample size of N=200 provides $> 85\%$ power to detect a 15% absolute difference in remission rates ($\alpha = 0.05$).
- Arm A: Standard of Care (ADA Guidelines).
- Arm B: Tier 2 Protocol (Hexa-Compound + Keto).
- Primary Endpoint: Proportion of participants achieving HbA1c $< 6.5\%$ without glucose-lowering medication at 12 months.
- Secondary Endpoints: Change in C-peptide (beta-cell recovery), HOMA-IR, ectopic fat content (MRI-PDFF), and hs-CRP.

4.4 Remission Probability Stratification

We propose a clinical decision algorithm for patient selection based on baseline biomarkers:

$$P_{\text{remission}} = \frac{1}{1 + e^{-z}} \tag{1}$$

Where:

$$\begin{aligned} z = {} & -2.5 + 0.8 \times C_{\text{peptide}} - 0.4 \times \text{HbA1c} \\ & - 0.3 \times \text{Duration}_{\text{years}} + 0.5 \times \text{HOMA-IR}^{-1} \end{aligned} \tag{2}$$

Example:

- Patient A: C-peptide = 3.5 ng/mL, HbA1c = 7.5%, Duration = 3 years, HOMA-IR = 4.0 $\rightarrow P_{\text{remission}} \approx 62\%$ (HIGH probability; Tier 2 candidate).
- Patient B: C-peptide = 1.2 ng/mL, HbA1c = 9.5%, Duration = 12 years, HOMA-IR = 8.0 $\rightarrow P_{\text{remission}} \approx 18\%$ (LOW probability; Tier 1 adjunct only).

5 SAFETY PROFILE & INTERACTION MANAGEMENT

A common criticism of multi-compound protocols is the risk of "polypharmacy." We address this directly via a proactive safety matrix.

5.1 CYP450 Interactions

Berberine is a known inhibitor of CYP3A4, CYP2D6, and CYP2C9.

- Risk: May elevate levels of drugs metabolized by these enzymes (e.g., statins, macrolides, warfarin).
- Mitigation: Patients on narrow therapeutic index drugs (e.g., warfarin) are excluded from Tier 2 unless strictly monitored. Statin dosage may need reduction.
- Synergy Note: Inhibition of glucuronidation by Piperine actually benefits the bioavailability of Resveratrol and Curcumin, turning a metabolic "bug" into a synergistic "feature."

5.2 Metabolic Acidosis Risk (SGLT2 Inhibitors)

A critical safety gate involves Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors (e.g., empagliflozin).

- Risk: Combining SGLT2 inhibitors with a ketogenic diet significantly increases the risk of Euglycemic Diabetic Ketoacidosis (euDKA).
- Protocol: SGLT2 inhibitors must be discontinued at least 48 hours prior to the initiation of the ketogenic nutrition phase in Tier 2, aligning with perioperative guidelines [8].

5.3 Hepatotoxicity Renal Safety

While high-dose extracts can stress the liver, the dosages selected are moderate and spread throughout the day.

- Monitoring: Baseline LFTs (ALT, AST) and eGFR are required.
- Exclusion: Active liver disease (ALT $> 3x$ ULN) or severe renal impairment (eGFR < 30).
- Benefit: Paradoxically, Berberine and Curcumin have demonstrated hepatoprotective effects in Non-Alcoholic Fatty Liver Disease (NAFLD), reducing liver fat and fibrosis markers.

6 DISCUSSION: THE PHASE TRANSITION MODEL

The failure of the current paradigm lies in its linearity. By treating T2DM as a glucose variable rather than a system state, we permit the underlying entropy to accumulate. The "Five-Loop" model explains why partial solutions fail: the network adapts.

6.1 Why Nutrition Alone Is Insufficient

While the ketogenic diet (as seen in Virta Health trials) effectively lowers glucose load, it does not necessarily repair the cellular machinery damaged by "Metabolic Memory" (epigenetic scarring). The addition of the Hexa-Compound Constellation addresses this residual entropy.

- Nutrition: Stops the influx of new damage (fuel overflow).
- Pharmacology: Repairs the existing damage (mitochondrial fission, inflammasome activation, senescent cell burden).

Without the pharmacological component, beta-cell redifferentiation may be incomplete, leaving the patient "glucose tolerant" but not "metabolically robust." Metformin is retained in the protocol not as a "glucose-lowerer" but as a foundational AMPK activator that synergizes with Berberine.

6.2 Thermodynamic Framing

We model health and disease as distinct basins of attraction in a potential energy landscape.

$$F = U - TS \tag{3}$$

Where F is Free Energy, U is metabolic stability, and S is systemic entropy. The diabetic state is a high-entropy attractor. Reversal requires a "high-amplitude intervention"—a threshold level of intervention intensity (ΔE) capable of pushing the system over the thermodynamic ridge separating these basins. This is not management; it is functional restoration.

7 LIMITATIONS & FUTURE DIRECTIONS

7.1 Evidence Gaps

- Synergy Data: Most compound interactions (Berberine + Resveratrol) demonstrated in animal models. Human RCT synergy data limited to lipid outcomes; HbA1c synergy not yet proven.
- IAPP Reversal: Mechanistic plausibility strong (fisetin disrupts β-sheet stacking); NO human biopsy data showing amyloid plaque dissolution post-intervention.
- Beta-Cell Resurrection: Lineage tracing confirms dedifferentiation reversibility in mice. Human proof limited to C-peptide recovery (indirect marker).
- Long-Term Durability: DiRECT trial showed 87% $\rightarrow$ 40% medication-free by year 5 (relapse common). Whether Hexa-Compound maintenance improves durability is untested.

7.2 Future Research Priorities

1. Tier 3 RCT: Prospective randomized trial (N=200) comparing Hexa-Compound protocol vs. standard care.
2. Mechanistic Validation: Pancreatic MRI (beta-cell volume), skin biopsy (IAPP oligomers), intestinal biopsy (GLP-1 cells) pre/post protocol.
3. Durability Cohort: 5-year follow-up assessing relapse predictors (weight, adherence, metabolic flexibility).

8 IMPLEMENTATION PATHWAYS

8.1 For Clinicians

- Immediate Action: Pilot Tier 1 protocol in early-stage patients (HbA1c $< 7.5\%$, C-peptide > 3 ng/mL).
- Safety First: Establish CGM + deprescribing protocols; avoid hypoglycemia via gradual insulin taper.
- Data Collection: Document outcomes (HbA1c, C-peptide, HOMA-IR) for institutional registry.

8.2 For Patients

- Self-Assessment: Use remission probability calculator (Section 4.4) to determine candidacy.
- Practitioner Engagement: Share manuscript + evidence registry with physician; request Tier 1 pilot.

9 CONCLUSION

T2DM is reversible. The β-cells are not dead; they are dormant. The metabolic network is not destroyed; it is entangled. By systematically dismantling the feedback loops of inflammation, oxidative stress, and lipotoxicity, we can restore metabolic sovereignty to the patient. This protocol moves beyond the "manage and delay" ethos of the 20th century into the "repair and reverse" paradigm of 21st-century systems medicine. We define success not by medication adherence, but by functional remission: HbA1c $< 6.5\%$ and HOMA-IR < 1.5 in the absence of pharmacotherapy.

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021.

[2] Everett, B. M., et al. "Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure." Circulation 139 (2018): 1289–1299.

[3] Supale, S., et al. "Loss of Maintenance of β-Cell Mass in Type 2 Diabetes." Diabetes Obes Metab 14 (2012): 1–11.

[4] Lean, M. E., et al. "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial." The Lancet 391.10120 (2018): 541–551.

[5] Mukherjee, A., et al. "Human Islet Amyloid Polypeptide: Clinical Implications and Future Perspectives." J Diabetes Res 2015 (2015).

[6] Talchai, C., et al. "Pancreatic β-Cell Dedifferentiation as a Mechanism of Diabetic β-Cell Failure." Cell 150.6 (2012): 1223–1234.

[7] Wang, J., et al. "Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy." Front. Pharmacol. 12 (2025).

[8] Handelsman, Y., et al. "American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis." Endocr Pract 22.6 (2016): 753–762.